Levofloxacin-d8

• Description :

  Levofloxacin-d8 is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

• Product Name Alternative :

  (-) -Ofloxacin-d8

• UNSPSC :

  12352005

• Target :

  Antibiotic; Bacterial

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Anti-infection

• Field of Research :

  Infection

• Purity :

  99.84

• Solubility :

  10 mM in DMSO|DMSO : 10mg/mL (ultrasonic) |H2O : ≥ 5mg/mL

• Smiles :

  O=C1C2=CC(F)=C(N3C([2H])([2H])C([2H])([2H])N(C([2H])([2H])C3([2H])[2H])C)C4=C2N(C=C1C(O)=O)[C@@H](C)CO4

• Molecular Formula :

  C18H12D8FN3O4

• Molecular Weight :

  369.42

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.; Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.; Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1217716-71-6]